



## Viridian Therapeutics to Present at Upcoming Investor Conferences

November 3, 2021

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Credit Suisse 30<sup>th</sup> Annual Healthcare Conference and participate in fireside chats at the Jefferies London Healthcare Conference and the Evercore ISI 4<sup>th</sup> Annual HealthCONx Conference.

### Credit Suisse 30<sup>th</sup> Annual Healthcare Conference

Format: Corporate Presentation  
Date: Monday, November 8, 2021  
Time: 8:50am EST

### Jefferies London Healthcare Conference

Format: Fireside Chat  
Date: Thursday, November 18, 2021  
Time: 8:00am GMT

[Webcast Link](#)

### Evercore ISI 4<sup>th</sup> Annual HealthCONx Conference

Format: Fireside Chat  
Date: Wednesday, December 1, 2021  
Time: 10:55am EST

[Webcast Link](#)

### About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating auto immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

### Viridian Contacts:

#### Investors:

Dan Ferry  
LifeSci Advisors  
617-430-7576  
[IR@viridiantherapeutics.com](mailto:IR@viridiantherapeutics.com)

#### Media:

Darby Pearson  
Verge Scientific Communications  
703-587-0831  
[PR@viridiantherapeutics.com](mailto:PR@viridiantherapeutics.com)